Clinovo Adds Enhancements to ClinCapture, the only free, full-validated EDC in the world
Clinovo launches the latest version of its Electronic Data Capture (EDC) system ClinCapture.
Sunnyvale, CA. December 19th, 2014. Clinovo launches the latest version of its Electronic Data Capture (EDC) system ClinCapture. With the new release, sponsor companies, contract research organizations (CROs) and researchers will be able to streamline the development and management of clinical trials by creating and managing electronic case report forms (CRFs) without relying on professional services. With these new features, ClinCapture becomes the only free, full-validated EDC in the world.
“We are very proud of this new release, which will deliver unprecedented speed of implementation, flexibility and functionality to users,” said Glenn Keet, CEO of Clinovo. “The new features of ClinCapture will give users the ability to create CRFs without having any sort of advanced programming or IT management skills, which represents a great leap forward in terms of usability for the industry.”
Through this release, ClinCapture is bringing its open source EDC system to the next level by offering at no cost a fully validated hosting environment. Furthermore, the new ClinCapture Builder is a do-it-yourself portal that enables users to fully create, deploy and manage studies on their own, from one central location. Because ClinCapture is cloud-based, users can manage one or several clinical trials from anywhere, at any time. Designing and creating CRFs will be faster and more straightforward with the drag-and-drop amenities, not to mention complex edit checks creation made simple-clinical trial managers can have these necessities completed in just a few days, making the processes extremely cost effective.
“The self-service portal sets ClinCapture apart from other EDCs,” said Marc Desgrousilliers, CTO at Clinovo. “Efficiency is essential in this industry, and having everything you need to build CRFs at your fingertips is exceptional. ClinCapture is also the only open source EDC with an integrated, intuitive randomization function and is one of the only WHO drug certified EDCs -proving Clinovo’s technological leadership.”
Clinovo’s intuitive technologies are designed to cater specifically to meet customers’ needs, budgets and infrastructures and are steering the industry; they offer best-in-class tools at a fraction of the cost. Clinovo seeks to provide the best way to streamline clinical trials to allow life science companies to save time and focus on what is most important to their business.
About Clinovo:
Clinovo is a technology focused Contract Research Organization (CRO) headquartered in the Silicon Valley. Clinovo streamlines clinical trials for life science companies globally by developing validated, intuitive eClinical systems. Clients claim over 50% cost savings using Clinovo’s Electronic Data Capture (EDC) system ClinCapture®, and CDISC Express, the first open source CDISC conversion tool. Services also include Biometrics Services, Staffing Solutions, and TechTrainings.
Contact information
Sophie McCallum
Director of Operations, Clinovo408-773-6258
sophie.mccallum@clinovo.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
